UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000026258
Receipt No. R000029323
Scientific Title Accompanying research of Phase II study for efficacy and safety of pembrolizumab for the cytotoxic chemotherapy unfit previously untreated patients highly expressing PD-L1 positive advanced non-small cell lung cancer (1888)
Date of disclosure of the study information 2017/03/27
Last modified on 2019/03/22 12:21:16

No. Disposal Last modified on Item of update
1 Insert 2017/02/21 23:19:49
2 Update 2017/02/21 23:21:32 Other related information
Other related information
3 Update 2017/03/25 10:11:37 Date of disclosure of the study information
4 Update 2017/03/25 10:12:50 Recruitment status
5 Update 2017/05/04 01:35:53 Anticipated trial start date
6 Update 2017/07/17 16:35:36 Recruitment status
Anticipated trial start date
Last follow-up date
Date of closure to data entry
7 Update 2019/03/22 12:18:14 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Organization
Organization
Address
Address
Tel
Email
8 Update 2019/03/22 12:21:16 Date of IRB
Last follow-up date
Date of closure to data entry


Contact us.